Fred Alger Management LLC Has $554,000 Holdings in CeriBell, Inc. $CBLL

Key Points

• Fred Alger Management LLC has reduced its stake in CeriBell, Inc. by 52.6%, resulting in ownership of 28,820 shares worth $554,000 at the end of the first quarter.
• CeriBell reported a revenue of $21.20 million for the quarter, surpassing analysts' expectations, while also posting a loss of ($0.38) earnings per share.
• The stock has seen a 3.5% decline recently, trading at $11.44, with a market cap of $419.39 million.

Fred Alger Management LLC reduced its stake in shares of CeriBell, Inc. (NASDAQ:CBLL - Free Report) by 52.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,820 shares of the company's stock after selling 31,941 shares during the quarter. Fred Alger Management LLC owned 0.08% of CeriBell worth $554,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new position in CeriBell during the 1st quarter valued at $175,000. Lord Abbett & CO. LLC raised its stake in CeriBell by 7.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock valued at $6,138,000 after purchasing an additional 23,451 shares during the last quarter. Nuveen LLC acquired a new position in CeriBell during the 1st quarter valued at $311,000. Swiss National Bank acquired a new position in CeriBell during the 1st quarter valued at $467,000. Finally, CenterBook Partners LP acquired a new position in shares of CeriBell in the 1st quarter valued at $3,531,000.

CeriBell Trading Down 3.5%

Shares of CBLL stock opened at $11.44 on Thursday. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $32.75. The stock has a market cap of $419.39 million and a price-to-earnings ratio of -3.83. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.91 and a current ratio of 13.31. The firm has a fifty day moving average of $13.82 and a 200-day moving average of $16.82.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. The company had revenue of $21.20 million during the quarter, compared to analysts' expectations of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Rebecca B. Robertson sold 11,188 shares of the company's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $17.85, for a total value of $199,705.80. Following the sale, the director owned 10,042 shares of the company's stock, valued at approximately $179,249.70. This represents a 52.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $17.70, for a total transaction of $442,500.00. Following the completion of the sale, the chief executive officer directly owned 776,022 shares in the company, valued at approximately $13,735,589.40. The trade was a 3.12% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,499 shares of company stock worth $1,126,402. 20.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Separately, BTIG Research assumed coverage on shares of CeriBell in a research note on Tuesday, June 24th. They issued a "buy" rating and a $30.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $32.14.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Want to see what other hedge funds are holding CBLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CeriBell, Inc. (NASDAQ:CBLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.